Cancer Immunotherapy is growing into an increased area of focus for research considering its ability to overcome the drawbacks of conventional radiation therapy. Antibody-based therapy predominates cancer immunotherapy. iRunway’s research found that 52% of patents in this space was related to cell surface antigen binding antibodies. Genentech, Bristol-Myers Squibb, Roche, University of California and University of Texas are among the leading patentees in this space. Read more!